DAPA-RESIST

Trial Sponsored by:

 

 

Trial Summary

DAPA-RESIST: Sodium glucose cotransporter-2 inhibitor DAPAgliflozin versus thiazide diuretic in patients with heart failure and diuretic RESISTance: a multi-centre, open-label, randomised controlled clinical trial

For many patients, particularly those with diabetes and pre-existing renal dysfunction, the usual treatment with intravenous (IV) loop diuretic may be ineffective. This situation, where escalating doses of loop diuretics do not produce an adequate diuresis is often termed “diuretic resistance”. The objective of this study is to gather evidence on the efficacy and safety of a strategy of combining dapagliflozin with intravenous furosemide, compared to combining the thiazide-like diuretic metolazone with IV furosemide, in patients with heart failure and diuretic resistance. The primary analysis will be in patients with HFrEF but patients with HFpEF will also be recruited in an ancillary study.


Investigators

Chief Investigator        

Dep Chief Investigator  

Co-Investigators

Trial Co-Ordinator


Patient Recruitment

Recruitment status: Pending